Ramucirumab for patients with intermediate-stage hepatocellular carcinoma (HCC) and elevated alpha fetoprotein (AFP): pooled results from two phase 3 studies (REACH and REACH-2)

Matthias Pinter; Masatoshi Kudo; RS Finn; M Morimot; K.-M. Rau; Masafumi Ikeda; Chia‐Jui Yen; Peter R. Galle; Josep M. Llovet; Bruno Daniele; Howard J. Lim; Khoon Lin Ling; Kazuko Yamaguchi‐Shinozaki; Reigetsu Yoshikawa; C Wang; Paolo Abada; Ryan C. Widau; Andrew X. Zhu

doi:10.1055/s-0040-1712319

Shared by

Josep M. Llovet

Ramucirumab for patients with intermediate-stage hepatocellular carcinoma (HCC) and elevated alpha fetoprotein (AFP): pooled results from two phase 3 studies (REACH and REACH-2)

Zeitschrift für Gastroenterologie

Article 2020 English

Authors

MP
Matthias Pinter
MK
Masatoshi Kudo
RF
RS Finn

Abstract

1 min read

Background REACH and REACH-2 investigated ramucirumab in patients with HCC after sorafenib. An exploratory analysis of outcomes by Barcelona Clinic Liver Cancer (BCLC) stage was performed.

Discussion(0)

No comments yet. Be the first to comment.

Ramucirumab for patients with intermediate-stage hepatocellular carcinoma (HCC) and elevated alpha fetoprotein (AFP): pooled results from two phase 3 studies (REACH and REACH-2)

Abstract

Discussion(0)

Related publications

Ramucirumab for patients with intermediate-stage hepatocellular carcinoma (HCC) and elevated alpha fetoprotein (AFP): Pooled results from two phase III studies (REACH and REACH-2).

Ramucirumab for Patients with Intermediate-Stage Hepatocellular Carcinoma and Elevated Alpha-Fetoprotein: Pooled Results from Two Phase 3 Studies (REACH and REACH-2)

Supplementary Material for: Ramucirumab for Patients with Intermediate-Stage Hepatocellular Carcinoma and Elevated Alpha-Fetoprotein: Pooled Results from Two Phase 3 Studies (REACH and REACH-2)

A study of ramucirumab (LY3009806) versus placebo in patients with hepatocellular carcinoma and elevated baseline alpha-fetoprotein (REACH-2).

Ramucirumab (RAM) for sorafenib intolerant patients with hepatocellular carcinoma (HCC) and elevated baseline alpha fetoprotein (AFP): Outcomes from two randomized phase 3 studies (REACH, REACH2).

Related publications

Article2020
Ramucirumab for patients with intermediate-stage hepatocellular carcinoma (HCC) and elevated alpha fetoprotein (AFP): Pooled results from two phase III studies (REACH and REACH-2).
Article2020

Article2021
Ramucirumab for Patients with Intermediate-Stage Hepatocellular Carcinoma and Elevated Alpha-Fetoprotein: Pooled Results from Two Phase 3 Studies (REACH and REACH-2)
Article2021

Dataset
Supplementary Material for: Ramucirumab for Patients with Intermediate-Stage Hepatocellular Carcinoma and Elevated Alpha-Fetoprotein: Pooled Results from Two Phase 3 Studies (REACH and REACH-2)

Article2018
A study of ramucirumab (LY3009806) versus placebo in patients with hepatocellular carcinoma and elevated baseline alpha-fetoprotein (REACH-2).
Article2018

Article2019
Ramucirumab (RAM) for sorafenib intolerant patients with hepatocellular carcinoma (HCC) and elevated baseline alpha fetoprotein (AFP): Outcomes from two randomized phase 3 studies (REACH, REACH2).
Article2019